This episode currently has no reviews.
Submit ReviewNetflix stock dropped after the company posted disappointing subscriber growth and earnings for the latest quarter. Plus results from Snap and Texas Instruments. And Institutional Investor’s Top-Rated Biotech Analyst breaks down the outlook for companies racing to bring a coronavirus vaccine to market. And a moment of zen for Kohl’s as the department store takes on a new project.
This episode currently has no reviews.
Submit ReviewThis episode could use a review! Have anything to say about it? Share your thoughts using the button below.
Submit Review